Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central anxious technique, conolidine modulates alternate molecular targets. A Science Advances analyze observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://stepheno118rih0.wikiexpression.com/user